Dyax receives FDA approval to expand use of Kalbitor (ecallantide) for the treatment of acute attacks of hereditary angioedema

04-04-2014 Business Wire HealthComments (0)

BiotechnologyDyax CorpKalbitorPharmaceuticalUSA

Dyax (NASDAQ:DYAX) today announced that the US Food and Drug Administration (FDA) has approved an expansion of the indication for KALBITOR (ecallantide), a peptide inhibitor of plasma kallikrein used in the treatment of acute hereditary angioedema (HAE) attacks, to include patients 12 years of age and older. With this approval, KALBITOR is the first and only subcutaneous therapy available to treat acute attacks of HAE in patients 12 years of age and o

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top